It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- NanoCarrier Submits CTA in EU for PII Study of NC-6004-Keytruda Combo for Head and Neck Cancer
January 11, 2019
- Daiichi Sankyo, Tokyo Institute of Technology Launch Open Innovation Research for Type 1 Diabetes Treatment Using iPS Cells
January 11, 2019
- Opdivo Extends OS in Second-Line Esophageal Cancer
January 10, 2019
- Chugai Completes Transfer of 13 Off-Patent Brands to Taiyo
January 10, 2019
- Kowa, Nissan Chemical Win US Patent Case over Livalo Crystal Form
January 10, 2019
- Meiji to Set Up JV with Canadian Firm to Develop Novel β-lactamase Inhibitor
January 9, 2019
- Eisai Recalls Azeptin after It Fails Dissolution Tests
January 9, 2019
- Investigator-Initiated US PII Study to Start for Telomelysin/Keytruda Combo: Oncolys
January 9, 2019
- Kyorin Introduces Voluntarily Recall of Desalex
January 9, 2019
- Fycompa Designated for Priority Review in China
January 9, 2019
- Takeda Completes £46 Billion Shire Acquisition
January 8, 2019
- Kyowa Kirin Files Burosumab in Japan
January 8, 2019
- Takeda Revving Up Collaboration Efforts on I/O Front
January 8, 2019
- Daiichi Sankyo Grabs Europe Rights to 1st-in-Class Cholesterol Drug
January 8, 2019
- Fujifilm to Make 10 Billion Yen Capital Investment in Bio CDMO Business
January 8, 2019
- Kaken Licenses Systemic Sclerosis Treatment from Corbus in Japan
January 8, 2019
- J-TEC’s Cell Sheet JACE Approved for Epidermolysis Bullosa
January 8, 2019
- Sumitomo Dainippon Corrects Announcement on US Latuda Settlement
January 7, 2019
- JCR Completes Patient Enrolment in Japan PIII Study for Hunter Syndrome Treatment
January 7, 2019
- Nipro to Strive for Stable Supply of Stemirac, 1st Stem Cell Therapy for Spinal Cord Injury
January 7, 2019
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…